Frédérick Durand

595 total citations
31 papers, 333 citations indexed

About

Frédérick Durand is a scholar working on Urology, Dermatology and Surgery. According to data from OpenAlex, Frédérick Durand has authored 31 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Urology, 9 papers in Dermatology and 7 papers in Surgery. Recurrent topics in Frédérick Durand's work include Hair Growth and Disorders (13 papers), Inflammatory Bowel Disease (7 papers) and Dermatology and Skin Diseases (6 papers). Frédérick Durand is often cited by papers focused on Hair Growth and Disorders (13 papers), Inflammatory Bowel Disease (7 papers) and Dermatology and Skin Diseases (6 papers). Frédérick Durand collaborates with scholars based in United States, United Kingdom and France. Frédérick Durand's co-authors include Peter C. Taylor, Bruno Fautrel, Rieke Alten, Bruce Kirkham, Inmaculada de la Torre, Nicole Desplaces, Valérie Zeller, Marie-Dominique Kitzis, Patrick Mamoudy and Jean-Marc Ziza and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Frédérick Durand

28 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédérick Durand United States	9	141	65	60	54	53	31	333
Parvaneh Hatami Iran	11	51 0.4×	46 0.7×	168 2.8×	30 0.6×	37 0.7×	58	352
Sibel Doğan Türkiye	11	63 0.4×	10 0.2×	108 1.8×	14 0.3×	28 0.5×	59	302
Neslihan Akdoğan Türkiye	10	58 0.4×	7 0.1×	158 2.6×	32 0.6×	65 1.2×	56	272
Shyue‐Luen Chang Taiwan	11	41 0.3×	13 0.2×	272 4.5×	19 0.4×	158 3.0×	31	525
Schmutz Jl France	12	95 0.7×	25 0.4×	167 2.8×	6 0.1×	101 1.9×	94	486
J.-C. Balblanc France	8	112 0.8×	11 0.2×	25 0.4×	7 0.1×	55 1.0×	12	351
Maria Chiara Ditto Italy	10	124 0.9×	31 0.5×	21 0.3×	3 0.1×	43 0.8×	33	348
Filipa Oliveira‐Ramos Portugal	10	90 0.6×	131 2.0×	12 0.2×	4 0.1×	38 0.7×	36	289
Amelia Spinella Italy	12	52 0.4×	16 0.2×	128 2.1×	9 0.2×	44 0.8×	37	358
Sami Giryes Israel	11	96 0.7×	59 0.9×	62 1.0×	2 0.0×	69 1.3×	22	409

Countries citing papers authored by Frédérick Durand

Since Specialization

Citations

This map shows the geographic impact of Frédérick Durand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérick Durand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérick Durand more than expected).

Fields of papers citing papers by Frédérick Durand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérick Durand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérick Durand. The network helps show where Frédérick Durand may publish in the future.

Co-authorship network of co-authors of Frédérick Durand

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérick Durand. A scholar is included among the top collaborators of Frédérick Durand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérick Durand. Frédérick Durand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lewis, James D., Aisha Vadhariya, Frédérick Durand, et al.. (2025). A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn’s Disease Activity Index: psychometric evaluation in adults with Crohn’s disease. Journal of Patient-Reported Outcomes. 9(1). 19–19.

Vermeire, Séverine, Bruce E. Sands, G. D’Haens, et al.. (2025). DOP005 Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension study. Journal of Crohn s and Colitis. 19(Supplement_1). i91–i93. 2 indexed citations

Lee, Scott D., Séverine Vermeire, Ryan C. Ungaro, et al.. (2025). Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study. The American Journal of Gastroenterology. 120(8). 1809–1819.

Chua, Laiyi, et al.. (2025). Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies. Clinical and Translational Science. 18(8). e70320–e70320. 1 indexed citations

Zlotogorski, Abraham, Sergio Vañó‐Galván, Bianca Maria Piraccini, et al.. (2024). Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials. SHILAP Revista de lepidopterología. 3(5). 1564–1569.

Bewley, Anthony, et al.. (2024). Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey. Clinical Cosmetic and Investigational Dermatology. Volume 17. 751–761. 4 indexed citations

Regueiro, Miguel, Aisha Vadhariya, Frédérick Durand, et al.. (2024). Psychometric evaluation of the Functional Assessment of chronic illness therapy–fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn’s disease. Quality of Life Research. 34(2). 509–521. 2 indexed citations

King, Brett, Manabu Ohyama, Maryanne M. Senna, et al.. (2024). Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. Journal of the American Academy of Dermatology. 92(2). 299–306. 4 indexed citations

Otani, Yasushi, et al.. (2024). P1044 Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn’s Disease. Journal of Crohn s and Colitis. 18(Supplement_1). i1873–i1873. 2 indexed citations

10.

Vañó‐Galván, Sergio, Alexander Egeberg, Bianca Maria Piraccini, et al.. (2024). Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries. Dermatology and Therapy. 14(4). 1027–1037. 5 indexed citations

11.

Craiglow, Brittany G., Yang Won Lee, Sergio Vañó‐Galván, et al.. (2024). Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology and Therapy. 14(7). 1959–1968. 3 indexed citations

12.

Craiglow, Brittany G., Yang Won Lee, Sergio Vañó‐Galván, et al.. (2023). 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials. Journal of the American Academy of Dermatology. 89(3). AB55–AB55. 1 indexed citations

13.

Vañó‐Galván, Sergio, Ulrike Blume‐Peytavi, Paul Farrant, et al.. (2023). Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries. Dermatology and Therapy. 13(12). 3121–3135. 12 indexed citations

14.

Vañó‐Galván, Sergio, Bianca Maria Piraccini, Pascal Reygagne, et al.. (2023). A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization. European Journal of Dermatology. 33(6). 648–656. 1 indexed citations

15.

Piraccini, Bianca Maria, Manabu Ohyama, Brittany G. Craiglow, et al.. (2023). Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine. 7(2). s186–s186. 3 indexed citations

16.

Piraccini, Bianca Maria, Manabu Ohyama, Brittany G. Craiglow, et al.. (2023). Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. SHILAP Revista de lepidopterología. 3(1). 242–248. 2 indexed citations

17.

Egeberg, Alexander, et al.. (2023). Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review. Dermatology and Therapy. 13(12). 2951–2991. 12 indexed citations

18.

Durand, Frédérick, et al.. (2021). Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent. Rheumatology and Therapy. 8(2). 921–935. 2 indexed citations

19.

Fautrel, Bruno, Rieke Alten, Bruce Kirkham, et al.. (2018). Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatology International. 38(6). 935–947. 84 indexed citations

20.

Soubrier, Martin, Jinglan Pei, Frédérick Durand, Lars Gullestad, & Ani John. (2016). Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy. 4(1). 133–149. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact